VYNE Share Price Performance
US$0.39
-1.61 (-80.50%)
Price US$0.39
Share PriceUS$0.39
We're A Little Worried About VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
Jun 27
VYNE Therapeutics Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
VYNE Community Narratives
There are no narratives available yet.
VYNE Therapeutics Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.51
- Gross Margin
- 100.00%
- Net Profit Margin
- -8,092.65%
- Debt/Equity Ratio
- 0%
VYNE Therapeutics Inc. Competitors
Snowflake Analysis
About VYNE
- Founded
- 2003
- Employees
- 13
- CEO
- WebsiteView website
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -1.1%
- 3 Months: 6.8%
- 1 Year: 15.5%
- Year to Date: 13.8%
Over the last 7 days, the market has dropped 1.1%, driven by a decline of 1.8% in the Information Technology sector. In the last year, the market is actually up 16%. Looking forward, earnings are forecast to grow by 16% annually. Market details ›